ACY-1215 (a selective HDAC6 inhibitor) could reduce renal fibrosis by inhibiting pro-fibrotic pathways (TGF-β/SMAD3, EGFR), myofibroblast activation, and inflammation [117]. Here, HDAC6 is linked to renal fibrosis.